Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(8):577-579; doi:10.1093/jnci/96.8.577
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ben-Ari, E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ben-Ari, E. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Dual Purpose: Some Cancer Therapies Used to Treat Autoimmune Diseases

Elia T. Ben-Ari

The first 150 words of the full text of this article appear below.

In July 1917, when German forces first used mustard gas (sulfur mustard) as a chemical warfare agent against British troops in Ypres, Belgium, no one would have predicted that any good would come of it. The first hint came in 1919, when E.B. and H.D. Krumbhaar reported that victims of mustard gas poisoning had low white blood cell counts and atrophy of the bone marrow and lymphatic tissues. These observations and subsequent research on the closely related nitrogen mustards ultimately led to clinical studies in the early 1940s showing that the nitrogen mustard compound mechlorethamine had beneficial effects in patients with Hodgkin disease and other lymphomas. The introduction of mechlorethamine into clinical practice launched the modern era of cancer chemotherapy.

Because of its immunosuppressive properties, nitrogen mustard was also one of the first cancer chemotherapy drugs used for treating other diseases—in particular, those that appeared to involve heightened or abnormal . . . [Full Text of this Article]

Established Therapies

New Research Directions

Future Trends and Challenges


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
Q. Chen, M. G. Espey, A. Y. Sun, C. Pooput, K. L. Kirk, M. C. Krishna, D. B. Khosh, J. Drisko, and M. Levine
From the Cover: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice
PNAS, August 12, 2008; 105(32): 11105 - 11109.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Li, W. K. Lim, S. P. Mahesh, B. Liu, and R. B. Nussenblatt
Cutting Edge: In Vivo Blockade of Human IL-2 Receptor Induces Expansion of CD56bright Regulatory NK Cells in Patients with Active Uveitis
J. Immunol., May 1, 2005; 174(9): 5187 - 5191.
[Abstract] [Full Text] [PDF]